Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
Late stage hormone refractory prostate cancer (HRPC) is presently incurable. Novel alternatives such as cytoreductive Gene Directed Enzyme Prodrug Therapy (GDEPT) offer great hope: The potential for in situ amplification of cytotoxicity due to GDEPT-associated "bystander effects" has special appeal for patients with prostate cancer, the prostate being dispensable. In this overview, recent developments in various GDEPT systems for treating prostate cancer are described. Research related to the enhancement of in situ GDEPT delivery and prostate cancer-targeting of viral vectors, is reviewed. The scope and progress of synergies between GDEPT and other treatment modalities, traditional and alternate, are discussed.
Khatri
Aparajita
A
Oncology Research Centre, Prince of Wales Hospital, Level 2, Clinical Sciences Building, Barker St., Randwick, NSW 2031, Australia.
Russell
Pamela J
PJ
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004798:Enzymes / Q000235:genetics / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000628:therapy*
D000970:Antineoplastic Agents; D004798:Enzymes; D011355:Prodrugs